- Home
- OGI vs CUE Comparison
OGI vs CUE Comparison
Compare OGI & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OGI | CUE |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.6M | 124.5M |
| IPO Year | 2015 | 2017 |
Fundamental Metrics
Financial Performance| Metric | OGI | CUE |
|---|---|---|
| Price | $0.93 | $32.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | ★ 399.6K | 126.7K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | $20.10 | N/A |
| Revenue Next Year | $13.92 | N/A |
| P/E Ratio | $13.91 | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $0.85 | $0.17 |
| 52 Week High | $2.24 | $45.50 |
Technical Indicators
Market Signals| Indicator | OGI | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 43.31 | 55.04 |
| Support Level | $0.92 | $24.49 |
| Resistance Level | $1.07 | $32.82 |
| Average True Range (ATR) | 0.05 | 4.44 |
| MACD | 0.01 | -0.13 |
| Stochastic Oscillator | 50.31 | 35.05 |
Price Performance
Historical ComparisonAbout OGI Organigram Holdings Inc.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.